Cargando…

Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling

BACKGROUND: Homeodomain-Interacting Protein Kinase 2 (HIPK2) has been reported to maintain basal cardiac function, however, its role in pathological cardiac remodeling remains unclear. METHODS: HIPK2 inhibitors (tBID and PKI1H) treated mice and two lines of HIPK2(−/−) mice were subjected to transver...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qiulian, Meng, Danni, Li, Feng, Zhang, Xiao, Liu, Li, Zhu, Yujiao, Liu, Shuqin, Xu, Minjun, Deng, Jiali, Lei, Zhiyong, Sluijter, Joost P.G., Xiao, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526139/
https://www.ncbi.nlm.nih.gov/pubmed/36182775
http://dx.doi.org/10.1016/j.ebiom.2022.104274
_version_ 1784800812518604800
author Zhou, Qiulian
Meng, Danni
Li, Feng
Zhang, Xiao
Liu, Li
Zhu, Yujiao
Liu, Shuqin
Xu, Minjun
Deng, Jiali
Lei, Zhiyong
Sluijter, Joost P.G.
Xiao, Junjie
author_facet Zhou, Qiulian
Meng, Danni
Li, Feng
Zhang, Xiao
Liu, Li
Zhu, Yujiao
Liu, Shuqin
Xu, Minjun
Deng, Jiali
Lei, Zhiyong
Sluijter, Joost P.G.
Xiao, Junjie
author_sort Zhou, Qiulian
collection PubMed
description BACKGROUND: Homeodomain-Interacting Protein Kinase 2 (HIPK2) has been reported to maintain basal cardiac function, however, its role in pathological cardiac remodeling remains unclear. METHODS: HIPK2 inhibitors (tBID and PKI1H) treated mice and two lines of HIPK2(−/−) mice were subjected to transverse aortic constriction (TAC). HIPK2 knockdown were performed in neonatal rat cardiomyocytes (NRCMs), neonatal rat cardiac fibroblasts (NRCFs), and human embryonic stem cell-derived cardiomyocytes (hESC-CMs). Microarray analysis was used to screen HIPK2 targets. Overexpression of early growth response 3 (EGR3) and C-type lectin receptor 4D (CLEC4D) were performed in NRCMs, while an activator of Smad3 was used in NRCFs, to rescue the effects of HIPK2 knockdown. Finally, the effects of EGR3 and CLEC4D knockdown by AAV9 in TAC were determined. FINDINGS: HIPK2 was elevated in TAC mice model, as well as cardiomyocyte hypertrophy and NRCFs fibrosis model. Pharmacological and genetic inhibition of HIPK2 improved cardiac function and suppressed cardiac hypertrophy and fibrosis induced by TAC. In vitro, HIPK2 inhibition prevented cardiomyocyte hypertrophic growth and NRCFs proliferation and differentiation. At the mechanistic level, we identified EGR3 and CLEC4D as new targets of HIPK2, which were regulated by ERK1/2-CREB and mediated the protective function of HIPK2 inhibition in cardiomyocytes. Meanwhile, inhibition of phosphorylation of Smad3 was responsible for the suppression of cardiac fibroblasts proliferation and differentiation by HIPK2 inhibition. Finally, we found that inhibition of EGR3 or CLEC4D protected against TAC. INTERPRETATION: HIPK2 inhibition protects against pathological cardiac remodeling by reducing EGR3 and CLEC4D with ERK1/2-CREB inhibition in cardiomyocytes, and by suppressing the phosphorylation of Smad3 in cardiac fibroblasts. FUNDING: This work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J.X.), National Natural Science Foundation of China (82020108002 and 81911540486 to J.X., 81400647 to MJ Xu), the grant from Science and Technology Commission of Shanghai Municipality (21XD1421300 and 20DZ2255400 to J.X.), the “Dawn” Program of Shanghai Education Commission (19SG34 to J.X.), and Shanghai Sailing Program (21YF1413200 to Q.Z.).
format Online
Article
Text
id pubmed-9526139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95261392022-10-02 Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling Zhou, Qiulian Meng, Danni Li, Feng Zhang, Xiao Liu, Li Zhu, Yujiao Liu, Shuqin Xu, Minjun Deng, Jiali Lei, Zhiyong Sluijter, Joost P.G. Xiao, Junjie eBioMedicine Articles BACKGROUND: Homeodomain-Interacting Protein Kinase 2 (HIPK2) has been reported to maintain basal cardiac function, however, its role in pathological cardiac remodeling remains unclear. METHODS: HIPK2 inhibitors (tBID and PKI1H) treated mice and two lines of HIPK2(−/−) mice were subjected to transverse aortic constriction (TAC). HIPK2 knockdown were performed in neonatal rat cardiomyocytes (NRCMs), neonatal rat cardiac fibroblasts (NRCFs), and human embryonic stem cell-derived cardiomyocytes (hESC-CMs). Microarray analysis was used to screen HIPK2 targets. Overexpression of early growth response 3 (EGR3) and C-type lectin receptor 4D (CLEC4D) were performed in NRCMs, while an activator of Smad3 was used in NRCFs, to rescue the effects of HIPK2 knockdown. Finally, the effects of EGR3 and CLEC4D knockdown by AAV9 in TAC were determined. FINDINGS: HIPK2 was elevated in TAC mice model, as well as cardiomyocyte hypertrophy and NRCFs fibrosis model. Pharmacological and genetic inhibition of HIPK2 improved cardiac function and suppressed cardiac hypertrophy and fibrosis induced by TAC. In vitro, HIPK2 inhibition prevented cardiomyocyte hypertrophic growth and NRCFs proliferation and differentiation. At the mechanistic level, we identified EGR3 and CLEC4D as new targets of HIPK2, which were regulated by ERK1/2-CREB and mediated the protective function of HIPK2 inhibition in cardiomyocytes. Meanwhile, inhibition of phosphorylation of Smad3 was responsible for the suppression of cardiac fibroblasts proliferation and differentiation by HIPK2 inhibition. Finally, we found that inhibition of EGR3 or CLEC4D protected against TAC. INTERPRETATION: HIPK2 inhibition protects against pathological cardiac remodeling by reducing EGR3 and CLEC4D with ERK1/2-CREB inhibition in cardiomyocytes, and by suppressing the phosphorylation of Smad3 in cardiac fibroblasts. FUNDING: This work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J.X.), National Natural Science Foundation of China (82020108002 and 81911540486 to J.X., 81400647 to MJ Xu), the grant from Science and Technology Commission of Shanghai Municipality (21XD1421300 and 20DZ2255400 to J.X.), the “Dawn” Program of Shanghai Education Commission (19SG34 to J.X.), and Shanghai Sailing Program (21YF1413200 to Q.Z.). Elsevier 2022-09-28 /pmc/articles/PMC9526139/ /pubmed/36182775 http://dx.doi.org/10.1016/j.ebiom.2022.104274 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Zhou, Qiulian
Meng, Danni
Li, Feng
Zhang, Xiao
Liu, Li
Zhu, Yujiao
Liu, Shuqin
Xu, Minjun
Deng, Jiali
Lei, Zhiyong
Sluijter, Joost P.G.
Xiao, Junjie
Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title_full Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title_fullStr Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title_full_unstemmed Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title_short Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
title_sort inhibition of hipk2 protects stress-induced pathological cardiac remodeling
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526139/
https://www.ncbi.nlm.nih.gov/pubmed/36182775
http://dx.doi.org/10.1016/j.ebiom.2022.104274
work_keys_str_mv AT zhouqiulian inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT mengdanni inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT lifeng inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT zhangxiao inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT liuli inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT zhuyujiao inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT liushuqin inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT xuminjun inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT dengjiali inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT leizhiyong inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT sluijterjoostpg inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling
AT xiaojunjie inhibitionofhipk2protectsstressinducedpathologicalcardiacremodeling